700 patients109,892 observations180 daysLIVE

CR-01 · Clinician Review

Clinician reviewSynthetic demo dataTarget state: Any deteriorating state · onset 5 d · prior: symptom −12%, persistence +15%, tolerance +10%Simulate for P-02657
For P-02657
Already tried by this patient. Among the 284 most similar trajectories: 11 accepted, 100% improved, mean effect −18%.
What it is

Clinician review: LIFE OS assembles a one-page summary (trajectory, divergence, theories, what was tried) and the investigator sees the patient within 72 hours. Autonomous guidance is suspended until the review.

How it works

An escalation, not a treatment. Used when the state is fragile, when evidence for any self-managed protocol is thin, or when pessimism and energy trackers indicate that a human conversation is the intervention.

What the patient does, day by day
Day 0🏥
Summary generated
LIFE OS insight + Human Model page exported for the clinician.
Day 1–3🏥
Clinician visit
Dose review, anti-emetic review, labs; decision recorded in LIFE OS.
After
Clinician plan in the companion
Whatever the clinician decides becomes the daily content.
Delivery
Owner
Investigator
Channel
Site visit or telehealth; summary attached
Duration
3 days
Touchpoints
One visit; follow-up plan written by the clinician
Cost
≈ €300 per patient (visit)
Monitoring
  • · Whatever the clinician orders
Stop rules
  • · n/a — the clinician decides
Contraindications
  • none recorded
Evidence in META-24
13 accepted · 100% improved · mean effect −17%
By biology segment
FUT2 non-secretorn 9100%
IL6 high-expression variantn 7100%
Low butyrate capacityn 8100%
Low microbial diversityn 10100%
By trajectory cluster
LTn 12100%
Works best when
  • · Toxicity ≥ 55 or discontinuation risk ≥ 75 %
  • · Pessimism > 7 with energy < 3
  • · No protocol clears the evidence bar
Works poorly when
  • · Used for patients a companion protocol would have handled (site burden)
What the model has learned about it

No learned rule yet for CR-01. Run learning after campaign results.

Campaigns using it

None yet. 158 patients look eligible right now.